Rentschler Biopharma SE’s New Advanced Production Line Now Fully Operational

Rentschler Biopharma SE, a contract development and manufacturing organization, announced that its new advanced production line in Milford, Massachusetts in now fully operational. According to the company, the product line represents the largest investment in its 150-year existence. Known as the Rentschler Biopharma Manufacturing Center, the facility reportedly doubles the company's global current Good Manufacturing Practice capacity and includes both 22,000 square feet of cleanroom space and four new 2,000-liter single-use bioreactors.¹

“As a fifth-generation, family-owned company, we stand at the forefront of manufacturing innovative therapies for patients with serious and rare diseases worldwide. The completion of our new, state-of-the-art production line is an important milestone for our company and emphasizes Rentschler Biopharma’s strong capabilities in the US. Our clients are our partners, and we are working with them to empower tomorrow’s therapies today. Indeed, in 2023, Rentschler Biopharma was proud to contribute to nearly 25% of the biopharmaceuticals approved by the US FDA. I would like to thank our teams on both sides of the Atlantic who worked tirelessly together to get this important facility online,” said Benedikt von Braunmühl, CEO, Rentschler Biopharma SE, in a press release.

Rentschler Biopharma first acquired the Milford site in 2019, expanding its size from 93,000 to 138,000 square feet. Originally a single-product commercial facility, the site now has the ability to produce multiple products in an up to 500L bioreactor setup.¹

“Our new line is vital to growing our business and effectively serving the U.S. market, and I am excited about bringing in new clients as well as expanding our support of existing ones with a reliability they can trust,” said Tom Roberts, president, Rentschler Biopharma Inc., General Manager, United States. “I also would like to extend my gratitude to the entire team for their strong support in getting this important new production line up and running. We are embarking on a new stage in our long and successful history and are poised to tackle the most complex challenges in biopharmaceutical development and manufacturing. In light of evolving industry legislation, we remain committed to supporting our clients responsibly and contributing positively to both national interests and global health advancements.”

Reference

1. Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational. GlobeNewswire. July 11, 2024. Accessed July 11, 2024. https://www.globenewswire.com/news-release/2024/07/11/2911756/0/en/Rentschler-Biopharma-Announces-New-State-of-the-Art-Production-Line-in-Massachusetts-is-Fully-Operational.html